Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

10468results about "Liposomal delivery" patented technology

Liposome as well as preparation method and application thereof in preparation of medicine for treating PARP inhibitor-resistant breast cancer

The invention provides a lipidosome, a preparation method thereof and application of the lipidosome in preparation of a medicine for treating PARP inhibitor-resistant breast cancer, and relates to the technical field of biology. The preparation method of the liposome provided by the invention comprises the following steps: under a stirring condition, injecting an ethanol solution dissolved with soybean phospholipid and cholesterol into a histidine aqueous solution for hydration, volatilizing an ethanol component after the hydration is finished, and carrying out ultrasonic treatment to prepare the liposome. The preparation method is simple and convenient, and the prepared liposome loaded with histidine is high in encapsulation efficiency. The research of the inventor finds that histidine metabolism reprogramming occurs in the PARPi resistance process of breast cancer cells, so that DNA synthesis repair is maintained. And after the PARPi-resistant breast cancer cells are treated by adopting the liposome disclosed by the invention, the histidine content in the breast cancer cells can be increased, so that the PARPi-resistant cells are sensitive to PARPi, and further the treatment on the PARPi-resistant breast cancer is realized.
Owner:WOMEN & CHILDRENS MEDICAL CENTER AFFILIATED WITH GUANGZHOU MEDICAL UNIVERSITY

Combination therapy

PCT designated stage expiredWO2025072649A1Antineoplastic agentsLiposomal delivery
A method for treating, inhibiting, or ameliorating cancer, such as KRAS-mutant cancer, including administering a GST-p inhibitor and either a KRAS inhibitor or a chemotherapy drug in therapeutically effective amounts to a subject suffering from the cancer in need thereof.
Owner:NITTO DENKO CORP

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticles comprising coding RNA molecules for use in gene editing and as vaccines and therapeutic agents

PCT designated stage expiredWO2024263729A1Organic chemistryAntiinfectivesDiseaseNanoparticle
The present disclosure describes improved LNP-based RNA vaccines, nucleobase editing systems, and therapeutics for use in treating and / or immunization against disease. In particular, the disclosure describes improved LNPs, including novel and improved ionizable lipids for making LNPs, that enhance the targeted delivery of LNP-based RNA vaccines and therapeutics based on linear and / or circular mRNAs. The improved LNPs protect linear and / or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced vaccines and / or therapeutic agents.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Polyglycerol stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056465A1SsRNA viruses positive-senseOrganic chemistry
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Polyphosphoester stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056467A1Organic active ingredientsGenetic material ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Polyvinylpyrrolidone stabilizing agents, compositions, uses, and manufacturing methods thereof

PCT designated stage expiredWO2025056466A1Organic chemistryPeptide/protein ingredients
The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.
Owner:GLOBAL LIFE SCI SOLUTIONS CANADA ULC +1

Manufacturing of bupivacaine multivesicular liposomes

ActiveUS12156940B1AntipyreticAnalgesicsPhysical chemistryMultivesicular liposomes
Embodiments of the present disclosure relates to a new and improved large scale commercial manufacturing process of making bupivacaine multivesicular liposomes (MVLs). Batches of bupivacaine MVLs prepared by the new process have high yields, improved stabilities, and desired particle size distributions.
Owner:PACIRA PHARMA INC

Pan-human coronavirus vaccines

The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Owner:MODERNATX INC

Cationic lipid containing two tertiary amine groups, and use thereof

Provided in the present invention is a new cationic lipid containing two tertiary amine groups. The structure is as shown in general formula (1), wherein the definition of each symbol in the formula is consistent with that described herein. The cationic lipid containing two tertiary amine groups is a pharmaceutically acceptable, biodegradable or highly biocompatible cationic lipid, and has the advantages of low toxicity, low immunogenicity and high biocompatibility. In the present invention, one or more biodegradable groups are contained between the hydrophilic head and the lipophilic tail chain of the cationic lipid containing two tertiary amine groups, thus preventing the endosome storage of an LNP prepared therefrom, increasing the endosome escape efficiency of the LNP in cells, and promoting the release of drugs into cytoplasm to serve the function thereof.
Owner:XIAMEN SINOPEG BIOTECH

Ionizable amine lipids

The disclosure provides ionizable lipids and lipid nanoparticle (LNP) compositions comprising ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.
Owner:INTELLIA THERAPEUTICS INC

Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Owner:ACUITAS THERAPEUTICS INC

Compounds and compositions and methods thereof for intracellular delivery of nucleic acid drugs

The present disclosure provides compounds according to Formulae I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII, XIII, XIII, and XIV for use as a component in a lipid nanoparticle composition for the delivery of biological and / or therapeutic agents. The present disclosure also provides novel, stable lipid nanoparticle compositions comprising one or more biological and / or therapeutic agents, as well as methods of making and delivering lipid nanoparticle compositions.
Owner:NANOTECH PHARMA INC

Method for stabilizing RNA

The invention relates to RNA molecules encoding an E. coli fimbrial H antigen (FimH). The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA 5 molecules, RNA-LNPs and compositions for the prevention of E. coli infection, including urinary tract infection.
Owner:PFIZER INC

Humanized Anti-CD8 antibodies and uses thereof

The present disclosure provides humanized antibodies and antigen binding domains thereof that bind CD8α and other antibody formats comprising these antigen binding domains, their use as a targeting moiety on lipid nanoparticles (tLNP) to deliver a therapeutic payload (such as a nucleic acid molecule) or other types of payloads. The present disclosure further relates to pharmaceutical compositions comprising the humanized anti-CD8α antibodies and CD8-targeted tLNP encapsulating a payload.
Owner:CAPSTAN THERAPEUTICS INC +5

Lipid nanoparticle formulations and compositions

PCT designated stage expiredWO2024249954A9Organic active ingredientsPowder delivery
Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Lipid nanoparticle formulations and compositions

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.
Owner:CAPSTAN THERAPEUTICS INC

Ginsenoside liposome as well as preparation method and application thereof

The invention discloses a ginsenoside liposome. The ginsenoside liposome comprises ginsenoside, phospholipid and a surfactant, and the ginsenoside comprises protopanoxadiol or / and protopanaxatriol. The invention also discloses a preparation method of the ginsenoside liposome and application of the ginsenoside liposome in preparation of medicines, cosmetics or skin care products. According to the invention, the final desugared product of ginsenoside with the effect of treating skin toxicity reaction is prepared into the liposome, so that the membrane permeation and absorption capabilities of ginsenoside are greatly improved, the skin toxicity caused by tumor treatment can be quickly and effectively relieved, and the drug effect can be played for a long time; the invention provides a new method for treating skin toxic reaction caused by tumor treatment, and makes up for the requirements which cannot be met by the existing treatment means.
Owner:SHANDONG BIYUAN BIOMEDICAL CO LTD +1

Compounds and compositions for intracellular delivery of therapeutic agents

The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and / or prophylactics such as RNA are useful in the delivery of therapeutic and / or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Owner:MODERNATX INC

Brain-targeted stem cell membrane bionic cationic liposome as well as preparation method and application thereof

The invention discloses brain-targeted stem cell membrane bionic cationic liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: extracting and purifying to obtain a stem cell membrane; preparing a cationic liposome; the stem cell membrane and the cationic liposome are fused to obtain the stem cell membrane bionic cationic liposome, and the relative dosage of the stem cell membrane and the cationic liposome is that the mass ratio of the total protein mass of the stem cell membrane to the total fat mass of the cationic liposome is 1: (2-24). The stem cell membrane bionic cationic liposome constructed by using the purified stem cell membrane has high brain targeting ability, low immune irritation and efficient nucleic acid drug carrying ability, can break through the blood brain barrier, realizes efficient targeting delivery of nucleic acid drugs to cells of the brain including neurons, and has good application prospects. Particularly, the polypeptide can be used as a targeted delivery platform of nucleic acid drugs for targeted therapy of cerebral diseases, especially cerebral arterial thrombosis.
Owner:ZHEJIANG UNIV

Mitochondria-targeted antioxidant hybrid vesicle as well as preparation method and application thereof

The invention provides a preparation method of mitochondria-targeted antioxidant hybrid vesicles. The preparation method comprises the following steps: S1, preparing and separating adipose-derived stem cell nano-vesicles; s2, preparing a liposome loaded with dihydromyricetin and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide by an ethanol injection method; and S3, preparing the hybrid nano vesicles loaded with the dihydromyricetin and the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-triphenylphosphine targeting peptide. The invention also provides the hybrid vesicles prepared by the method and application of the hybrid vesicles in preparation of refractory diabetes wound treatment drugs. The lipidosome and the adipose-derived stem cell nano-vesicles are hybridized to prepare the hybridized vesicles capable of targeting mitochondria and resisting oxidation, the hybridized vesicles are applied to wound treatment for the first time, the problem of oxidative stress of diabetic wounds is solved, wound healing is accelerated, and a new strategy is provided for optimizing mitochondrial function defects and oxidative stress of the diabetic wounds.
Owner:XIEHE HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI & TECH UNIV

Ionizable lipids

The application relates to ionizable lipids. The formulations of ionizable lipids can be used for the delivery of one or more nucleic acid therapeutic agents, for example mRNA, siRNA or miRNA. The compositions can include additional lipids, such as non-cationic lipids, PEG-modified lipids and optionally cholesterol.
Owner:BRISTOL MYERS SQUIBB CO

Lipids and compositions thereof

Provided herein are lipids having the Formula I or Formula Ia:and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X1, X2, and n are as defined herein for Formula I and Formula Ia, respectively. Also provided herein are lipid nanoparticle (LNP) compositions comprising lipid having the Formula I or Ia and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).
Owner:GENERATION BIO CO

Cationic lipids for use in lipid nanoparticles

Compounds are provided having the following structure:or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein a, b, c, d, G1, G2, L1, L2, R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8 and X are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, nanoparticles comprising the compounds and methods for their use and preparation are also provided.
Owner:ACUITAS THERAPEUTICS INC

Methods for treating pulmonary non-tuberculous mycobacterial infections

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and / or NTM culture conversion to negative during or after the administration period.
Owner:INSMED INC

Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle compositions comprising same

The present disclosure provides lipid nanoparticle compositions comprising a nucleic acid encoding a therapeutic polypeptide. The disclosure also provides novel IL-15 polypeptides, fusion proteins comprising the IL-15 polypeptides, and nucleic acids encoding the IL-15 polypeptides and the fusion proteins.
Owner:星锐医药(苏州)有限公司